132 related articles for article (PubMed ID: 17093973)
1. A decision-support model for evaluating changes in biopharmaceutical manufacturing processes.
Chhatre S; Francis R; O'Donovan K; Titchener-Hooker NJ; Newcombe AR; Keshavarz-Moore E
Bioprocess Biosyst Eng; 2007 Jan; 30(1):1-11. PubMed ID: 17093973
[TBL] [Abstract][Full Text] [Related]
2. Decision-support software for the industrial-scale chromatographic purification of antibodies.
Chhatre S; Thillaivinayagalingam P; Francis R; Titchener-Hooker NJ; Newcombe AR; Keshavarz-Moore E
Biotechnol Prog; 2007; 23(4):888-94. PubMed ID: 17630695
[TBL] [Abstract][Full Text] [Related]
3. The integrated simulation and assessment of the impacts of process change in biotherapeutic antibody production.
Chhatre S; Jones C; Francis R; O'Donovan K; Titchener-Hooker N; Newcombe A; Keshavarz-Moore E
Biotechnol Prog; 2006; 22(6):1612-20. PubMed ID: 17137309
[TBL] [Abstract][Full Text] [Related]
4. Global Sensitivity Analysis for the determination of parameter importance in bio-manufacturing processes.
Chhatre S; Francis R; Newcombe AR; Zhou Y; Titchener-Hooker N; King J; Keshavarz-Moore E
Biotechnol Appl Biochem; 2008 Oct; 51(Pt 2):79-90. PubMed ID: 18205624
[TBL] [Abstract][Full Text] [Related]
5. A prototype software methodology for the rapid evaluation of biomanufacturing process options.
Chhatre S; Francis R; O'Donovan K; Titchener-Hooker NJ; Newcombe AR; Keshavarz-Moore E
Biotechnol Appl Biochem; 2007 Oct; 48(Pt 2):65-78. PubMed ID: 17868020
[TBL] [Abstract][Full Text] [Related]
6. A software tool to assist business-process decision-making in the biopharmaceutical industry.
Mustafa MA; Washbrook J; Lim AC; Zhou Y; Titchener-Hooker NJ; Morton P; Berezenko S; Farid SS
Biotechnol Prog; 2004; 20(4):1096-102. PubMed ID: 15296435
[TBL] [Abstract][Full Text] [Related]
7. Medium term planning of biopharmaceutical manufacture using mathematical programming.
Lakhdar K; Zhou Y; Savery J; Titchener-Hooker NJ; Papageorgiou LG
Biotechnol Prog; 2005; 21(5):1478-89. PubMed ID: 16209554
[TBL] [Abstract][Full Text] [Related]
8. Application of agent-based system for bioprocess description and process improvement.
Gao Y; Kipling K; Glassey J; Willis M; Montague G; Zhou Y; Titchener-Hooker NJ
Biotechnol Prog; 2010; 26(3):706-16. PubMed ID: 20014420
[TBL] [Abstract][Full Text] [Related]
9. An automated packed protein G micro-pipette tip assay for rapid quantification of polyclonal antibodies in ovine serum.
Chhatre S; Francis R; Bracewell DG; Titchener-Hooker NJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Nov; 878(30):3067-75. PubMed ID: 20951101
[TBL] [Abstract][Full Text] [Related]
10. Medium term planning of biopharmaceutical manufacture with uncertain fermentation titers.
Lakhdar K; Farid SS; Titchener-Hooker NJ; Papageorgiou LG
Biotechnol Prog; 2006; 22(6):1630-6. PubMed ID: 17137311
[TBL] [Abstract][Full Text] [Related]
11. Aqueous two-phase systems: A viable platform in the manufacturing of biopharmaceuticals.
Rosa PA; Ferreira IF; Azevedo AM; Aires-Barros MR
J Chromatogr A; 2010 Apr; 1217(16):2296-305. PubMed ID: 19962707
[TBL] [Abstract][Full Text] [Related]
12. Multiobjective long-term planning of biopharmaceutical manufacturing facilities.
Lakhdar K; Savery J; Papageorgiou LG; Farid SS
Biotechnol Prog; 2007; 23(6):1383-93. PubMed ID: 17924645
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of an industrial affinity process used in the manufacturing of digoxin-specific polyclonal Fab fragments.
Thillaivinayagalingam P; O'Donovan K; Newcombe AR; Keshavarz-Moore E
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Mar; 848(1):88-96. PubMed ID: 16720112
[TBL] [Abstract][Full Text] [Related]
14. A methodology for the comparative evaluation of alternative bioseparation technologies.
Tran R; Zhou Y; Lacki KM; Titchener-Hooker NJ
Biotechnol Prog; 2008; 24(5):1007-25. PubMed ID: 19194909
[TBL] [Abstract][Full Text] [Related]
15. A computer-aided approach to compare the production economics of fed-batch and perfusion culture under uncertainty.
Lim AC; Washbrook J; Titchener-Hooker NJ; Farid SS
Biotechnol Bioeng; 2006 Mar; 93(4):687-97. PubMed ID: 16259001
[TBL] [Abstract][Full Text] [Related]
16. Flexibility--the guiding principle for antibody manufacturing.
Carson KL
Nat Biotechnol; 2005 Sep; 23(9):1054-8. PubMed ID: 16151390
[TBL] [Abstract][Full Text] [Related]
17. A tool for modeling strategic decisions in cell culture manufacturing.
Farid SS; Novais JL; Karri S; Washbrook J; Titchener-Hooker NJ
Biotechnol Prog; 2000; 16(5):829-36. PubMed ID: 11027178
[TBL] [Abstract][Full Text] [Related]
18. The state of biopharmaceutical manufacturing.
Molowa DT; Mazanet R
Biotechnol Annu Rev; 2003; 9():285-302. PubMed ID: 14650933
[TBL] [Abstract][Full Text] [Related]
19. Manufacturing, regulatory and commercial challenges of biopharmaceuticals production: a Finnish perspective.
Närhi M; Nordström K
Eur J Pharm Biopharm; 2005 Apr; 59(3):397-405. PubMed ID: 15760720
[TBL] [Abstract][Full Text] [Related]
20. Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies.
Przybylowski M; Bartido S; Borquez-Ojeda O; Sadelain M; Rivière I
Vaccine; 2007 Jun; 25(27):5013-24. PubMed ID: 17537555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
